Business
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results
ICESECRET study interim findings presented at the Urological Association Conference in Eilat, IsraelProSense was found to be a safe and effective treatment
About this update from Icecure Medical Ltd.
[{"type":"text","content":"ICESECRET study interim findings presented at the Urological Association Conference in Eilat, IsraelProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgeryProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countriesCAESAREA, Israel, Dec. 19, 2022 /PRNewswire/ --- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced interim results from the ICESECRET study for the treatment of patients with small renal masses (\"SRM\") who cannot be offered kidney-preserving surgery. Data were presented on December 14, 2022 at the Urological Association Conference in Eilat, Israel. The presentation titled \"Renal Mass Cryoablation - Interim Analysis ICESECRET Study\" was delivered by Dr. Nasir Said of Bnai Zion Medical Center.\nAccording to the presentation, out of the 115 patients enrolled, 107 patients (112 lesions) returned for follow-up with a mean duration of 22.8 months and a range 12-60 months.\nIn a subgroup of patients with no previous history of kidney cancer on the same kidney and a lesion ≤3 cm, an 89.5% recurrence-free rate was observed at a mean follow-up time of 22.2 months when the procedure protocol was followed.The recurrence-free rate was 85.1% for the 107 patients (91 patients, including 13 patients who underwent a second cryoablation), at a mean follow-up period of 16.5 months.5 serious adverse events were reported, 4 of which were of mild severity and were treated conservatively and resolved within 1-5 days, with one severe complication of a new onset of ipsilateral hydronephrosis 7 months after the cryoablation procedure that led to nephrectomy.Cryoablation time and hospitalization time were relatively short, up to approximately 25 minutes and 2 days, respectively.The presentation concluded that, based on these interim results, cryoablation is safe and effective for treating renal masses under 5 cm.According to the American Journal of Roentgenology, small renal masses, which may be malignant or benign tumors in the kidney, have been rising in incidence over the past two decades. According to the American Can...